WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: MARCH ISSUE PUBLISHED

    MARCH 2023 Issue has been successfully launched on 1 March 2023.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR March 2023 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

STATUS OF (PD-L1) EXPRESSION IN HODGKIN LYMPHOMA IN A SET OF IRAQI PATIENTS

*Arshan Aqeel Abdullah, Dr. Mohammed Fawzi Alqanbar and Dr. Mohammed Shnain Ali

ABSTRACT

Introduction: Hodgkin Lymphoma is a hematolymphoid malignancy that can affect any age group worldwide. Both genders can be affected by Hodgkin lymphoma with slight predilection for male gender. Involvement by Hodgkin lymphoma range from single node to wide spread disease. Although it has a successful story to response to conventional therapies, there still a proportion of patients who are refractory to primary therapy and those who relapse after prolong courses of therapy. The aim of study is to Show PD-L1 expression in Iraqi Hodgkin lymphoma. PD-L1 expression and Hodgkin lymphoma clinicopathologic status should be correlated. PD-L1 expression in primary and refractory/relapsed patients. Method: This cross-sectional study gathered thirty paraffin blocks from thirty Hodgkin lymphoma patients from the histo-pathological lab. Two 5-?m portions per block. One segment was stained with hematoxylin and eosin and the other with monoclonal rabbit anti-Human PD-L1 E1L3N[R] antibody. The positive threshold was 1%, hence the case was termed negative when <1% of tumour cells expressed PD-L1, low when 1-49%, and high when > 50%. Negative, weak, moderate, and severe staining were rated. Results: 90% of patients had positive PD-L1 and 10% had negative. PD-L1 expression was high (73.3%) and low (16.7%) in those staining positively. PD-L1 staining correlated with age (P< 0.05), whereas gender, Hodgkin lymphoma histologic subtypes, clinical stage, initial disease, refractory/relapsed condition, and tumour cell CD30 and CD15 expression did not. Conclusion: Most Hodgkin Lymphoma tumour cells expressed PD-L1. Older people expressed more PD-L1, but other clinicopathologic markers did not correlate. Novel PD-L1 medication should provide equivalent results in initial disease and refractory/relapsed patients.

[Full Text Article]